for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc (ADR)

AZN.OQ

Latest Trade

54.70USD

Change

0.00(-0.00%)

Volume

3,297,201

Today's Range

53.33

 - 

54.70

52 Week Range

36.15

 - 

64.94

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
54.70
Open
54.56
Volume
3,297,201
3M AVG Volume
96.70
Today's High
54.70
Today's Low
53.33
52 Week High
64.94
52 Week Low
36.15
Shares Out (MIL)
1,312.30
Market Cap (MIL)
144,736.80
Forward P/E
27.65
Dividend (Yield %)
2.53

Next Event

AstraZeneca PLC at Redburn CEO Conference (Virtual)

Latest Developments

More

Serum Institute Of India CEO Says Can Supply Up To 400 Mln Doses Of Astrazeneca Vaccine By July 2021- CNBC- TV18

Astrazeneca Says AZD1222 Vaccine Can Be 90% Effective Against Covid-19

Adage Capital Partners GP, L.L.C. Dissolves Share Stake In Pfizer; Ups Stake in Biogen, ViacomCBS

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AstraZeneca plc (ADR)

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Industry

Biotechnology & Drugs

Contact Info

1 Francis Crick Avenue

CB2 0AA

United Kingdom

+44.20.73045000

https://www.astrazeneca.com/Home

Executive Leadership

Leif Johansson

Independent Non-Executive Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Marc Dunoyer

Chief Financial Officer, Executive Director

Katarina Ageborg

Executive Vice President - Sustainability, Chief Compliance Officer

Fiona Cicconi

Executive Vice President - Human Resources

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.5K

2018

22.1K

2019

24.4K

2020(E)

26.3K
EPS (USD)

2017

2.140

2018

1.730

2019

1.750

2020(E)

2.000
Price To Earnings (TTM)
58.16
Price To Sales (TTM)
5.59
Price To Book (MRQ)
11.90
Price To Cash Flow (TTM)
23.00
Total Debt To Equity (MRQ)
183.18
LT Debt To Equity (MRQ)
153.78
Return on Investment (TTM)
5.59
Return on Equity (TTM)
3.93

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up